Patents by Inventor David T. Hung

David T. Hung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8546381
    Abstract: This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: October 1, 2013
    Assignee: Medivation Technologies, Inc.
    Inventors: David T. Hung, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain
  • Patent number: 8338408
    Abstract: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: December 25, 2012
    Assignee: Medivation Technologies, Inc.
    Inventors: David T. Hung, Andrew A. Protter, Rajendra P. Jain, Sundeep Dugar, Sarvajit Chakravarty, Sergey O. Bachurin, Anatoly K. Ustinov, Bogdan K. Beznosko, Nadezhda Sergeevna Beznosko, legal representative, Elena F. Shevtsova, Vladimir V. Grigoriev
  • Patent number: 8338447
    Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds of formula (I) are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: December 25, 2012
    Assignee: Medivation Technologies, Inc.
    Inventors: David T. Hung, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra P. Jain, Sundeep Dugar
  • Patent number: 8178493
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Grant
    Filed: April 6, 2009
    Date of Patent: May 15, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
  • Publication number: 20120034644
    Abstract: Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 9, 2012
    Applicant: Atossa Genetics, Inc.
    Inventor: David T. Hung
  • Publication number: 20100216814
    Abstract: This disclosure is directed to pyrido[4,3-b]indoles having rigid moieties. The compounds in one embodiment are pyrido[4,3-b]indoles having an unsaturated hydrocarbon moiety. The compounds in another embodiment are pyrido[4,3-b]indoles having a cycloalkyl, cycloalkenyl or heterocyclyl moiety. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: October 30, 2009
    Publication date: August 26, 2010
    Inventors: David T. HUNG, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Publication number: 20100178277
    Abstract: The invention provides compositions and methods for treating, preventing, delaying the onset, and/or delaying the development of a disease or condition for which the activation, differentiation, and/or proliferation of one or more cell types is beneficial. These compositions and methods include, for example, a hydrogenated pyrido[4,3-b]indole such as dimebon and/or a cell that has been incubated with a hydrogenated pyrido[4,3-b]indole such as dimebon. In some embodiments, the compositions and methods also include a growth factor and/or an anti-cell death compound. The invention also provides methods of activating a cell, promoting the differentiation of a cell, and/or promoting the proliferation of a cell by incubating the cell with one or more hydrogenated pyrido[4,3-b]indoles or pharmaceutically acceptable salts thereof. In some embodiments, the cell is also incubated with one or more growth factors and/or anti-cell death compounds.
    Type: Application
    Filed: May 23, 2008
    Publication date: July 15, 2010
    Applicant: MEDIVATION NEUROLOGY, INC.
    Inventors: David T. Hung, Andrew Asher Protter
  • Publication number: 20100152108
    Abstract: The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.
    Type: Application
    Filed: October 26, 2007
    Publication date: June 17, 2010
    Applicant: MEDIVATION NEUROLOGY, INC.
    Inventors: David T. Hung, Andrew Asher Protter
  • Publication number: 20100152163
    Abstract: This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided.
    Type: Application
    Filed: October 30, 2009
    Publication date: June 17, 2010
    Inventors: David T. Hung, Andrew Asher Protter, Rajendra Parasmal Jain, Sarvajit Chakravarty
  • Publication number: 20100099667
    Abstract: This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: March 24, 2009
    Publication date: April 22, 2010
    Inventors: David T. Hung, Andrew Asher Protter, Sarjavit Chakravarty, Rajendra Parasmal Jain
  • Publication number: 20100022580
    Abstract: This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: January 26, 2009
    Publication date: January 28, 2010
    Inventors: David T. Hung, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra Parasmal Jain
  • Publication number: 20090270412
    Abstract: This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: March 24, 2009
    Publication date: October 29, 2009
    Inventors: David T. HUNG, Andrew Asher Protter, Sarvajit Chakravarty, Rajendra P. Jain, Sundeep Dugar
  • Publication number: 20090239854
    Abstract: This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    Type: Application
    Filed: October 27, 2008
    Publication date: September 24, 2009
    Inventors: David T. HUNG, Andrew A. PROTTER, Rajendra P. JAIN, Sundeep DUGAR, Sarvajit CHAKRAVARTY, Sergey O. BACHURIN, Anatoly K. USTINOV, Bogdan K. BEZNOSKO, Elena F. SHEVTSOVA, Vladimir V. GRIGORIEV, Nadezhda Sergeevna Beznosko
  • Publication number: 20090221504
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Application
    Filed: April 6, 2009
    Publication date: September 3, 2009
    Applicants: Novartis Vaccines and Diagnostics, Inc., Duke University
    Inventors: David T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
  • Patent number: 7531511
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: May 12, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: David T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
  • Publication number: 20040018546
    Abstract: Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.
    Type: Application
    Filed: July 21, 2003
    Publication date: January 29, 2004
    Applicant: Cytyc Health Corporation
    Inventor: David T. Hung
  • Patent number: 6638727
    Abstract: The invention is to methods for identifying asymptomatic patients who have a likelihood of benefiting from administration of an estrogen activity modulator for risk reduction or therapeutic treatment of breast cancer, methods for reducing risk or therapeutically treating these asymptomatic patients, and methods for monitoring the treatments.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: October 28, 2003
    Assignee: Cytyc Health Corporation
    Inventors: David T. Hung, Susan Love
  • Publication number: 20030171294
    Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis.
    Type: Application
    Filed: March 24, 2003
    Publication date: September 11, 2003
    Applicant: Chiron Corporation
    Inventors: David T. Hung, Brian H. Annex, Kevin P. Landolfo, W. Michael Kavanaugh
  • Patent number: 6610484
    Abstract: Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.
    Type: Grant
    Filed: July 26, 2000
    Date of Patent: August 26, 2003
    Assignee: Cytyc Health Corporation
    Inventor: David T. Hung
  • Publication number: 20030060415
    Abstract: The invention is a treatment for coronary conditions by delivering a therapeutic agent to the pericardial space. The therapeutic agent can be delivered by internal entry through the atrium or venticle, or by external entry through the chest cavity. The therapeutic agent can be a polypeptide, polynucleotide or other drug.
    Type: Application
    Filed: October 2, 2002
    Publication date: March 27, 2003
    Applicant: Chiron Corporation
    Inventor: David T. Hung